Recent

% | $
Quotes you view appear here for quick access.

Ruby Tuesday, Inc. Message Board

wall_street_titan 199 posts  |  Last Activity: 21 hours ago Member since: Jan 27, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Something Is Just Not Right

    by raybestos76 23 hours ago
    wall_street_titan wall_street_titan 21 hours ago Flag

    Right now, even though Athersys is a focal point of everyone on this board, in the big scheme of things in biotech, Athersys is just another anonymous biotech company with hopes and dreams and there are many. Institutions generally don't get interested until there is Phase II data, especially in a company with such a low float where taking a meaningful position is not possible without driving up the shares. I rather not say any more because if this doesn't work you will be the first one to point fingers. Everyone here understands the risks and the potential rewards.

    WST

    Sentiment: Strong Buy

  • Reply to

    Something Is Just Not Right

    by raybestos76 23 hours ago
    wall_street_titan wall_street_titan 22 hours ago Flag

    Explain what?? If you, or anyone else, expects an answer on the stroke results based on the trading leading up to the trial you are barking up the wrong tree. Here's an example of closing prices from from Intercept Pharmaceuticals before positive liver results in a Phase II:

    10/01/13 - $76.82
    01/08/14 - $72.39
    01/09/14 - $275.87 Results Announced.

    Shares peaked at over $450 and now trade at $263

    Again, there are no guarantees here and the risks are high. However, given the wealth of independent scientific data, the Chugai partnership and the fact the results are being presented at a high profile international stroke conference, I'll take my chances with a full understanding of the risks. Raybstos76, it seems you may have already sold out of your shares as I have not KNOWN you to display doubts publically on any positions you own. If you haven't made a decision yet on Athersys, do your own DD and draw your own conclusions in any way you see fit. I have no way to draw any conclusion based on the way the shares will trade in the next couple of weeks and neither does anyone else unless of course the secrets lie in some type of secret formula tied to the VWAP.

    WST

    Sentiment: Strong Buy

  • "This excellent study by Dr. Dahlke and his co-authors demonstrate the potential for multipotent adult progenitor cells to serve as a universal cell product. Being able to reduce the level of immunosuppressant drugs post-transplant could have significant benefits to patients,” said Anthony Atala, M.D., Editor-in-Chief of SCTM. “This study represents a promising pathway for clinical immunotherapy, and I congratulate our Young Investigator Award winner on this important accomplishment.”"

    prwebDOTcom/releases/2015/02/prweb12490041.htm

    WST

    Sentiment: Strong Buy

  • Reply to

    Wasting Money On Higher Priced May Options

    by raybestos76 Mar 27, 2015 3:28 PM
    wall_street_titan wall_street_titan Mar 27, 2015 3:44 PM Flag

    The article did not say that. It only stated that the stroke presentation will take place on Sunday April 19 at 8:50 AM local time. the actual date that Athersys decides to release data in a press release is still an unknown.

    WST

    Sentiment: Strong Buy

  • wall_street_titan wall_street_titan Mar 26, 2015 9:31 PM Flag

    SA isn't telling you the details, I am, and as usual I provided a link so readers could check it out themselves. I just beat Athersys IR on this one although GVB told us this would be the venue. I also strongly disagree with your theory that presenting in front of researchers foretells mediocre results. On the contrary, this is a leading stroke conference with key opinion leaders in the field. What better place to make a splash. Aren't there many strokes occurring in the EU? Most would conclude that presenting at a high profile venue, with the stakes so high, would be a positive sign.

    WST

    Sentiment: Strong Buy

  • Reply to

    Data Release Date

    by alfuture1 Mar 26, 2015 7:41 PM
    wall_street_titan wall_street_titan Mar 26, 2015 8:34 PM Flag

    Hard to imagine GVB and Robert Mays flying out to Glasgow to an International Stroke Conference, among all the expectations, and reporting dud results.

    WST

    Sentiment: Strong Buy

  • wall_street_titan wall_street_titan Mar 26, 2015 9:21 AM Flag

    Based on the mechanism of action, if MultiStem works at 30 days the stroke patient will not lose those benefits at 90 days, IMHO. The reason I say this is because the first couple of weeks is the period of time when the damage is done by the over inflammatory response of the spleen. This overreaction is mitigated by MultiStem in the earlier days after treatment by shutting down the brain/blood barrier. Once the patient gets beyond this stage, the neurotrophic factors start to kick in and hopefully provide further benefit, as some level of healing and takes place and new blood vessels begin to form. By the 30th day the bulk, if not all, of the potential secondary damage threat from the spleen has passed. This is not comparable to UC which is not an acute injury but a chronic systemic disease that may need multiple dosing to get over the hump. We can't know for sure if multiple doses would have worked in UC unless another double blinded placebo controlled trial is commenced.

    The stakes are high here and it is human nature to look at every move up and down in the share price as a validation or a warning of the upcoming results. I would guess that all the modeling to analyze the data is set up ahead of the unblinding so the PI won't need much time to put it all together. I don't know but I'm guessing GvB will do everything in his power to keep a very tight lid on these data once they are unblinded.

    WST

    Sentiment: Strong Buy

  • wall_street_titan by wall_street_titan Mar 25, 2015 6:00 PM Flag

    I did not delete the comment. It was nothing earth shattering buty during the Alliance for Regenerative Medicine conference today, JK pointed out how he believes MultiStem works for UC, as he was interviewing the CEO of TX Cell about this:

    vasave®, TxCell lead product candidate, is a personalized T cell immunotherapy product, based on the properties of autologous ovalbumin-specific regulatory T lymphocytes. A phase IIb placebo controlled study (CATS29) has been initiated for refractory Crohn's disease. Ovasave® is classified as Advanced Therapy Medicinal Product (ATMP) by the European Medicines Agency EMA.

    WST

    Sentiment: Strong Buy

  • Reply to

    NBI Getting Hit Hard Today

    by wall_street_titan Mar 25, 2015 12:07 PM
    wall_street_titan wall_street_titan Mar 25, 2015 1:05 PM Flag

    .NBI is the Nasdaq Biotechnology Index. Good news is that even though it is down even more than before, -3.50%, ATHX is slowly rebounding.

    WST

    Sentiment: Strong Buy

  • wall_street_titan by wall_street_titan Mar 25, 2015 12:07 PM Flag

    I don't think this is specific to ATHX. Algo trading could have taken it down and stop orders placed because of the run up could have exacerbated the move down. We've seen a couple of days like this out of nowhere recently but the shares rebounded quickly. Ugly day but has nothing to do with stoke data, IMHO. All Biotechs are getting hit hard today. NBI down 2.75%.

    WST

    Sentiment: Strong Buy

  • SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc.(CYTX) announced today that it will formally launch and showcase its new Celase® GMP enzyme at the 2015 International Society for Cellular Therapy (ISCT) annual meeting on May 27th to 30th in Las Vegas. This will mark the first time that Cytori has made Celase® GMP available for purchase as a standalone product.

    Celase® is a proprietary enzyme blend that was designed specifically to optimize Cytori’s automated adipose tissue dissociation process. Celase® is produced using avian and mammalian tissue-free raw materials, aseptic processes and sterile filtration under cGMP guidelines.

    “Celase® GMP’s unique, best-in-class formulation is the result of significant investment made by Cytori,” said Dr. Marc Hedrick, President and CEO of Cytori Therapeutics(CYTX). “By making Celase® GMP broadly available to researchers, we believe Cytori can simultaneously accelerate the cell therapy field, de-risk clinical implementation and enhance our cash flows. This represents a clear win-win scenario for all parties.”

    Integrating Celase® GMP into cell isolation study protocols can facilitate a smooth transition from bench and animal research to downstream clinical applications. Celase® has been approved by the U.S. FDA for use in clinical trials evaluating Cytori Cell Therapy™ in patients with chronic heart failure, osteoarthritis of the knee and hand manifestations of scleroderma.

    “Each day our goal is to deliver the best possible health care to our patients. Using a clinical grade enzyme such as Celase® to generate a safe and high quality cell output to treat patients helps us attain this goal,” said Dr. Maurizio Calcagni, Vice Chairman of the Division of Plastic Surgery and Hand Surgery at University Hospital Zurich.

    continued....

    Sentiment: Buy

  • Reply to

    Osteoarthritis and Stem Cells

    by wall_street_titan Mar 23, 2015 7:04 PM
    wall_street_titan wall_street_titan Mar 24, 2015 12:13 PM Flag

    There is strong evidence that ADRCs work on osteoarthritis. Maybe not as strong as with scleroderma but strong, nonetheless. What is just as exciting is that Cytori will have a monopoly if the FDA chooses to enforce its own rules and put the hundreds of stem cell clinics operating throughout the USA today, out of business.

    WST

    Sentiment: Strong Buy

  • wall_street_titan by wall_street_titan Mar 23, 2015 7:04 PM Flag

    ADRCs have been used in animals successfully for many years. this is a huge market for Cytori that they will likely succeed in:

    news-medicalDOTnet/news/20150323/Stem-cell-treatment-for-osteoarthritis-of-the-knee-may-help-rebuild-lost-cartilage.aspx

    WST

    Sentiment: Buy

  • Reply to

    Lets Be Realistic Here

    by wall_street_titan Mar 23, 2015 11:39 AM
    wall_street_titan wall_street_titan Mar 23, 2015 11:49 AM Flag

    NO. There was no one was impersonating anyone on this board prior to UC data. This is pure desperation by shorts and it is doing absolutely nothing but make the impersonator look like an idiot and HELPING the shares rise further.

    Do your own DD.

    WST

    Sentiment: Strong Buy

  • wall_street_titan by wall_street_titan Mar 23, 2015 11:39 AM Flag

    The shorts are getting desperate, resorting to impersonation because they are unable to honestly look at all the evidence out there and make a valid argument. All the evidence points to positive stroke results and now the share price is just beginning to confirm this. Imitation is the best for of flattery. Thanks for the compliment :)! Just trying to understand why some would continue this impersonation strategy when it fools no one and simply drives up the share price. Got to love it, keep at it.

    Wall street Titan

    Sentiment: Strong Buy

  • SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc.(CYTX) will present data from two preclinical studies describing safety and efficacy of ADRCs for treatment of thermal burn injuries at the Annual Meeting of the American Burn Association (ABA) in Chicago on April 21-24, 2015. This research, funded by the contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services, was part of the package of data submitted to the US Government as part of the In-Process Review meeting that led to the execution of the current contract option valued at $14.1 million, and part of Cytori’s $106 million BARDA contract framework.

    The first presentation will describe the use of Cytori Cell Therapy in combination with a widely used skin substitute in a full thickness burn injury model. Data to be presented show increased wound vascularity and maturation in wounds treated with Cytori Cell Therapy. The second presentation will describe a novel model of full thickness thermal burn injury with concomitant radiation exposure. Data to be presented demonstrate that delivery of Cytori Cell Therapy accelerates wound re-epithelialization in this context. These data will form the basis of an Investigational Device Exemption (IDE) package to be submitted to FDA for a proposed clinical trial using Cytori Cell Therapy in thermal burn injury.

    “These are encouraging data that support the advancement of Cytori Cell Therapy to accelerate wound healing in severe burn patients,” said Dr. Tenenhaus, a plastic surgeon from UCSD Burn Center who specializes in reconstructive surgery for burns and other traumatic injuries. Dr. Marc Hedrick, President and CEO of Cytori commented: “We remain focused on continuing execution of key deliverables under our BARDA contract and believe that, when coupled with ongoing research and development activities, the data to be presented at ABA will support an FDA IDE approval and unlocking of the next BARDA milestone, which includes $8.3 million in clinical trial funding. We look forward to their full publication in the scientific literature in the near future.”

    The treatment of thermal burns remains a critical underserved medical need. Despite standard of care primarily consisting of dressings, skin grafts and skin substitutes, patients frequently suffer from pain, scarring, skin contracture and reduced range of motion. Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring.

    According to the American Burn Association, there were approximately 450,000 burn injuries in 2013 that required medical treatment in the United States, with approximately 40,000 requiring hospitalization. In a mass casualty event, the Government Accountability Office reports that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event.

    Sentiment: Buy

  • wall_street_titan by wall_street_titan Mar 20, 2015 1:38 PM Flag

    If you look at the dollar volume of trading relative to larger pharmaceutical companies you can appreciate how far under the radar screens Athersys lies. At 1:35 EST, just $3,414,000 worth of shares have traded hands. Peanuts for a company on the verge of showing data that could potential treat most of the 15,000,000 patients who suffer a stroke each year on a global basis. Either we got this wrong or the big players on Wall Street are just totally missing this. Maybe its too small for the big players to participate without pushing it up dramatically. We may look back at this with amazement.

    On another not, this Athersys video was published in October 2014: youtubeDOTcom/watch?v=RYsqPxMWH1I Most have probably seen it.

    Would Athersys invest the money and time to produce this unless they had great confidence? There has been no non tax-related insider selling by management so that can't be it.

    WST

    Sentiment: Strong Buy

  • Reply to

    GvB Skipping NYC Conference for Japan... Hmmmmm

    by mrfuelcell Mar 19, 2015 1:08 PM
    wall_street_titan wall_street_titan Mar 19, 2015 1:54 PM Flag

    Yet another subtle hint that Stroke is a go in Japan.

    WST

    Sentiment: Strong Buy

  • Reply to

    GvB Skipping NYC Conference for Japan... Hmmmmm

    by mrfuelcell Mar 19, 2015 1:08 PM
    wall_street_titan wall_street_titan Mar 19, 2015 1:47 PM Flag

    Atheresys is a co-sponsor so this event is surely a big deal for them. Surely other Big Pharma participants will be inquiring after the Chugai deal with regard to other indications that may be ready to go in Japan.

    WST

    Sentiment: Strong Buy

  • Reply to

    GvB Skipping NYC Conference for Japan... Hmmmmm

    by mrfuelcell Mar 19, 2015 1:08 PM
    wall_street_titan wall_street_titan Mar 19, 2015 1:45 PM Flag

    I've attended the NYC conference the last 2 years. It is not a partnership conference. More of an investor focused conference. Looks like I'll skip it this year since both Cytori and Athersys won't be presenting.

    WST

    Sentiment: Strong Buy

RT
6.0403+0.0103(+0.17%)9:40 AMEDT